Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Articles|December 14, 2017
Management of Locoregional Recurrence in Breast Cancer
Author(s)William J. Gradishar, MD
This video highlights an education session from SABCS on the management of locoregional recurrence in breast cancer.
Advertisement
In this video, William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago, reviews the management of locoregional recurrence in breast cancer.
Gradishar took part in a session on this topic at the 2017 San Antonio Breast Cancer Symposium (SABCS), held December 5–9 in San Antonio, Texas.
Advertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
2
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
3
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
4
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
5